New pill shows promise for rare bleeding disorder in phase 3 trial
Disease control
Ongoing
This study tested an oral drug called rilzabrutinib in 232 adults and adolescents with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants received either the drug or a placebo twice dail…
Phase: PHASE3 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated May 17, 2026 02:04 UTC